ANAPTYSBIO INC. - COMMON STOCK

Anaptys Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

27 Feb 2025 16:15:00 By Nasdaq GlobeNewswire

Anaptys Announces Participation in March Investor Conferences

27 Feb 2025 16:15:00 By Nasdaq GlobeNewswire

Anaptys Announces Rosnilimab Achieved Positive Results in RA Phase 2b Trial and Highest Ever Reported CDAI LDA Response Over 6 Months

12 Feb 2025 07:30:05 By Nasdaq GlobeNewswire

Anaptys to Announce Top-line Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, in Rheumatoid Arthritis on Feb. 12, 2025

11 Feb 2025 17:30:00 By Nasdaq GlobeNewswire

Anaptys to Present at the Guggenheim SMID Cap Biotech Conference

03 Feb 2025 16:15:00 By Nasdaq GlobeNewswire

Vanda Pharmaceuticals and Anaptys Announce Exclusive Global License Agreement for Vanda to Develop and Commercialize Imsidolimab, an IL-36R Antagonist

03 Feb 2025 07:30:17 By Nasdaq GlobeNewswire

Anaptys to Present at the 43rd Annual J.P. Morgan Healthcare Conference

07 Jan 2025 09:15:00 By Nasdaq GlobeNewswire

Anaptys Announces Phase 2b Trial of ANB032, a BTLA Agonist, Did Not Meet Primary or Secondary Endpoints in Atopic Dermatitis

11 Dec 2024 08:30:00 By Nasdaq GlobeNewswire

Anaptys Announces Third Quarter 2024 Financial Results and Provides Business Update

05 Nov 2024 16:15:00 By Nasdaq GlobeNewswire

Anaptys Announces Participation in November and December Investor Conferences

05 Nov 2024 16:15:00 By Nasdaq GlobeNewswire

Anaptys Announces Participation in September Investor Conferences

29 Aug 2024 09:15:00 By Nasdaq GlobeNewswire

Anaptys Announces Pricing of $100 Million Underwritten Registered Direct Offering

14 Aug 2024 05:00:00 By Nasdaq GlobeNewswire

Anaptys Announces Second Quarter 2024 Financial Results and Provides Business Update

05 Aug 2024 16:15:00 By Nasdaq GlobeNewswire

Anaptys Announces First Quarter 2024 Financial Results and Provides Business Update

09 May 2024 16:15:00 By Nasdaq GlobeNewswire

Anaptys Announces Positive Top-Line GEMINI-2 Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)

09 May 2024 16:10:00 By Nasdaq GlobeNewswire

Anaptys to Receive $50 Million in a Capped Non-Recourse Monetization from Amended Agreement with Sagard in Exchange for Additional Jemperli Royalties

09 May 2024 16:05:01 By Nasdaq GlobeNewswire

Anaptys Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

11 Mar 2024 16:15:00 By Nasdaq GlobeNewswire

Anaptys to Present at TD Cowen’s 44th Annual Health Care Conference and 2024 AAD Annual Meeting

29 Feb 2024 09:15:00 By Nasdaq GlobeNewswire

Anaptys to Present at Guggenheim’s 6th Annual Biotechnology Conference

31 Jan 2024 09:15:00 By Nasdaq GlobeNewswire

Anaptys Expands Immune Cell Modulator Pipeline with Exclusive License to BDCA2 Modulator Antibody Portfolio from Centessa Pharmaceuticals

27 Nov 2023 16:15:00 By Nasdaq GlobeNewswire